Prostate cancer immunotherapy: the role for sipuleucel-T and other immunologic approaches
Arlen, P.M.
Oncology 25(3): 261-262
2011
ISSN/ISBN: 0890-9091 PMID: 21548469 Document Number: 650875
Document emailed within 1 workday
Related Documents
Harris, D.T.; Matyas, G.R.; Gomella, L.G.; Talor, E.; Winship, M.D.; Spitler, L.E.; Mastrangelo, M.J. 1999: Immunologic approaches to the treatment of prostate cancer Seminars in Oncology 26(4): 439-447Minev, B.R.; Guo, F.; Gueorguieva, I.; Kaiser, H.E. 2002: Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects In Vivo 16(6): 405-415
Rosenberg, S.A.; Lotze, M.T.; Mulé, J.J. 1988: NIH conference. New approaches to the immunotherapy of cancer using interleukin-2 Annals of Internal Medicine 108(6): 853-864
Fourcade, R-Olivier.; Richaud, P.; Coloby, P.; Malavaud, B. 2007: Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 17(4 Suppl. 1): 891-910
Van der Meijden, A.P. 1992: New approaches to intravesical chemo-immunotherapy in superficial bladder cancer Progress in Clinical and Biological Research 378: 95-101
Sarosdy, M.F. 1997: Oral bropirimine immunotherapy of rodent prostate cancer European Urology 31(Suppl): 5-9
Muhrer, K.H.; Kahle, M.; Pasurka, B. 1983: Immunoreactivity in colorectal cancer. Approaches for an immunologic diagnosis? Schweizerische Medizinische Wochenschrift 113(15): 546-547
Fradet, Y. 1991: Molecular and immunologic approaches in the management of bladder cancer Urologic Clinics of North America 18(3): 515-524
Kipp, R.T.; McNeel, D.G. 2007: Immunotherapy for prostate cancer - recent progress in clinical trials Clinical Advances in Hematology and Oncology: H&o 5(6): 465-474; 477-479
Hwang, C.; Sanda, M.G. 1999: Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy Current Opinion in Molecular Therapeutics 1(4): 471-479
Saha, K.; Kapila, H.; Madan, R.; Shinghal, R.N. 1986: Immunologic tools to decipher efficacy of BCG immunotherapy in advanced breast cancer: a one year follow up study Asian Pacific Journal of Allergy and Immunology 4(2): 139-148
Bostwick, D.G. 1994: Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer American Journal of Clinical Pathology 102(4 Suppl 1): S31-S37
Hardeman, S.W.; Wake, R.W.; Soloway, M.S. 1989: Two new techniques for evaluating prostate cancer. The role of prostate-specific antigen and transrectal ultrasound Postgraduate Medicine 86(2): 197-8 201 204 Passim
Topuzov, M.E. 2007: Role of density of prostate-specific antigen transitory zone in early diagnosis of prostate cancer Voprosy Onkologii 53(3): 295-297
Wallen, E.M. 2006: Treatment for localized prostate cancer: surgical approaches North Carolina Medical Journal 67(2): 146-148
Satoh, T.; Ishiyama, H. 2017: Current multidisciplinary approaches for metastatic prostate cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 75(4): 620-625
Veliev, E.I. 2002: Modern approaches to treating locally-advanced and disseminated prostate cancer Terapevticheskii Arkhiv 74(10): 67-70
Mathé, G.; Halle-Pannenko, O.; Bourut, C. 1973: BCG in cancer immunotherapy: results obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immunoprophylaxis or immunotherapy National Cancer Institute Monograph 39(8): 107-113
Novick, A.C. 1995: Current surgical approaches, nephron-sparing surgery, and the role of surgery in the integrated immunologic approach to renal-cell carcinoma Seminars in Oncology 22(1): 29-33
Wu, C.T.; Chuang, C.K.; Chou, C.C.; Chu, S.H.; Chen, H.W.; Chen, C.S.; Chiang, Y.J.; Liao, S.K. 2000: The role of free to total prostate-specific antigen ratio for prostate cancer in screening patients with total serum levels between 4 and 20 ng/ml Chang Gung Medical Journal 23(3): 142-148